GABA interneurons mediate the rapid antidepressant-like effects of scopolamine

Journal of Clinical Investigation

Volumn 126, Issue 7, 2016, Pages 2482-2494

  Wohleb, Eric S ^a   Wu, Min ^a   Gerhard, Danielle M ^b   Taylor, Seth R ^a   Picciotto, Marina R ^a   Alreja, Meenakshi ^a   Duman, Ronald S ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; MESSENGER RNA; MUSCARINIC M1 RECEPTOR; PARVALBUMIN; SCOPOLAMINE; SHORT HAIRPIN RNA; SOMATOSTATIN; ANTIDEPRESSANT AGENT; SCOPOLAMINE BROMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ANXIETY; ARTICLE; BEHAVIOR CHANGE; BRAIN SLICE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; ELECTROPHYSIOLOGY; FEMALE; GABAERGIC SYSTEM; GLUTAMATERGIC SYNAPSE; IMMUNOHISTOLOGY; INTERNEURON; MALE; MEDIAL PREFRONTAL CORTEX; MOUSE; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL; PROTEIN EXPRESSION; PYRAMIDAL NERVE CELL; REPEATED DRUG DOSE; TRANSGENIC MOUSE; ANIMAL; ANIMAL BEHAVIOR; C57BL MOUSE; DEPRESSIVE DISORDER, MAJOR; DRUG EFFECTS; HUMAN; METABOLISM; PREFRONTAL CORTEX;

ANIMALS; ANTIDEPRESSIVE AGENTS; ANXIETY; BEHAVIOR, ANIMAL; DEPRESSIVE DISORDER, MAJOR; ELECTROPHYSIOLOGY; FEMALE; GABAERGIC NEURONS; HUMANS; INTERNEURONS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PREFRONTAL CORTEX; SCOPOLAMINE HYDROBROMIDE;

EID: 84978386315     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI85033     Document Type: Article

References (54)

1. Kessler RC The costs of depression. Psychiatr Clin North Am. 2012; 35 (1):1-14.
2. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005; 62 (6):617-627.
3. Murray CJ, et al. The state of US health, 1990-2010: burden of diseases, injuries, and risk factors. JAMA. 2013; 310 (6):591-608.
4. Simon GE Social and economic burden of mood disorders. Biol Psychiatry. 2003; 54 (3):208-215.
5. Souery D, Papakostas GI, Trivedi MH. Treatment-resistant depression. J Clin Psychiatry. 2006; 67 (suppl 6):16-22.
6. Drevets WC, Zarate CA Jr, Furey ML. Antidepressant effects of the muscarinic cholinergic receptor antagonist scopolamine: a review. Biol Psychiatry. 2013; 73 (12):1156-1163.
7. Furey ML, Khanna A, Hoffman EM, Drevets WC. Scopolamine produces larger antidepressant and antianxiety effects in women than in men. Neuropsychopharmacology. 2010; 35 (12):2479-2488.
8. Furey ML, Drevets WC. Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. Arch Gen Psychiatry. 2006; 63 (10):1121-1129.
9. Voleti B, et al. Scopolamine rapidly increases mammalian target of rapamycin complex 1 signaling, synaptogenesis, and antidepressant behavioral responses. Biol Psychiatry. 2013; 74 (10):742-749.
10. Duman RS, Aghajanian GK. Synaptic dysfunction in depression: potential therapeutic targets. Science. 2012; 338 (6103):68-72.
11. Li N, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010; 329 (5994):959-964.
12. Rajkowska G. Postmortem studies in mood disorders indicate altered numbers of neurons and glial cells. Biol Psychiatry. 2000; 48 (8):766-777.
13. Rajkowska G, et al. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry. 1999; 45 (9):1085-1098.
14. Drevets WC Functional anatomical abnormalities in limbic and prefrontal cortical structures in major depression. Prog Brain Res. 2000; 126:413-431.
15. Radley JJ, et al. Repeated stress alters dendritic spine morphology in the rat medial prefrontal cortex. J Comp Neurol. 2008; 507 (1):1141-1150.
16. Radley JJ, et al. Repeated stress induces dendritic spine loss in the rat medial prefrontal cortex. Cereb Cortex. 2006; 16 (3):313-320.
17. Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature. 2008; 455 (7215):894-902.
18. Kang HJ, et al. Decreased expression of synapserelated genes and loss of synapses in major depressive disorder. Nat Med. 2012; 18 (9):1413-1417.
19. Ota KT, et al. REDD1 is essential for stress induced synaptic loss and depressive behavior. Nat Med. 2014; 20 (5):531-535.
20. Miller OH, Moran JT, Hall BJ. Two cellular hypotheses explaining the initiation of ketamine's antidepressant actions: Direct inhibition and disinhibition. Neuropharmacology. 2016; 100:17-26.
21. Wohleb ES, Gerhard D, Thomas A, Duman RS. Molecular cellular mechanisms of rapid-acting antidepressants ketamine scopolamine. Curr Neuropharmacol. 2016; 21 (3):454-464.
22. Witkin JM, et al. M1 and m2 muscarinic receptor subtypes regulate antidepressant-like effects of the rapidly acting antidepressant scopolamine. J Pharmacol Exp Ther. 2014; 351 (2):448-456.
23. Navarria A, et al. Rapid antidepressant actions of scopolamine: role of medial prefrontal cortex and M1-subtype muscarinic acetylcholine receptors. Neurobiol Dis. 2015; 82:254-261.
24. Disney AA, Reynolds JH. Expression of m1-type muscarinic acetylcholine receptors by parvalbumin-immunoreactive neurons in the primary visual cortex: a comparative study of rat, guinea pig, ferret, macaque, and human. J Comp Neurol. 2014; 522 (5):986-1003.
25. Yamasaki M, Matsui M, Watanabe M. Preferential localization of muscarinic M1 receptor on dendritic shaft and spine of cortical pyramidal cells and its anatomical evidence for volume transmission. J Neurosci. 2010; 30 (12):4408-4418.
26. Amar M, Lucas-Meunier E, Baux G, Fossier P. Blockade of different muscarinic receptor subtypes changes the equilibrium between excitation and inhibition in rat visual cortex. Neuroscience. 2010; 169 (4):1610-1620.
27. Perrotti LI, et al. Induction of deltaFosB in reward-related brain structures after chronic stress. J Neurosci. 2004; 24 (47):10594-10602.
28. Markram H, Toledo-Rodriguez M, Wang Y, Gupta A, Silberberg G, Wu C. Interneurons of the neocortical inhibitory system. Nat Rev Neurosci. 2004; 5 (10):793-807.
29. Gupta A, Wang Y, Markram H. Organizing principles for a diversity of GABAergic interneurons and synapses in the neocortex. Science. 2000; 287 (5451):273-278.
30. Malkesman O, et al. The female urine sniffing test: a novel approach for assessing rewardseeking behavior in rodents. Biol Psychiatry. 2010; 67 (9):864-871.
31. Lieben CK, Blokland A, Sik A, Sung E, van Nieu wenhuizen P, Schreiber R. The selective 5-HT6 receptor antagonist Ro4368554 restores memory performance in cholinergic and serotonergic models of memory deficiency in the rat. Neuro psychopharmacology. 2005; 30 (12):2169-2179.
32. Falsafi SK, Deli A, Höger H, Pollak A, Lubec G. Scopolamine administration modulates muscarinic, nicotinic and NMDA receptor systems. PLoS One. 2012; 7 (2):e32082.
33. Singh P, Konar A, Kumar A, Srivas S, Thakur MK. Hippocampal chromatin-modifying enzymes are pivotal for scopolamine-induced synaptic plasticity gene expression changes and memory impairment. J Neurochem. 2015; 134 (4):642-651.
34. Kawaguchi Y. Selective cholinergic modulation of cortical GABAergic cell subtypes. J Neurophysiol. 1997; 78 (3):1743-1747.
35. Gulledge AT, Park SB, Kawaguchi Y, Stuart GJ. Heterogeneity of phasic cholinergic signaling in neocortical neurons. J Neurophysiol. 2007; 97 (3):2215-2229.
36. McCormick DA, Prince DA. Two types of muscarinic response to acetylcholine in mammalian cortical neurons. Proc Natl Acad Sci U S A. 1985; 82 (18):6344-6348.
37. Neske GT, Patrick SL, Connors BW. Contributions of diverse excitatory and inhibitory neurons to recurrent network activity in cerebral cortex. J Neurosci. 2015; 35 (3):1089-1105.
38. Silberberg G, Markram H. Disynaptic inhibition between neocortical pyramidal cells mediated by Martinotti cells. Neuron. 2007; 53 (5):735-746.
39. Lin LC, Sibille E. Somatostatin, neuronal vulnerability and behavioral emotionality. Mol Psychiatry. 2015; 20 (3):377-387.
40. Soumier A, Sibille E. Opposing effects of acute versus chronic blockade of frontal cortex somatostatin-positive inhibitory neurons on behavioral emotionality in mice. Neuropsycho-pharmacology. 2014; 39 (9):2252-2262.
41. Sibille E, Morris HM, Kota RS, Lewis DA. GABA related transcripts in the dorsolateral prefrontal cortex in mood disorders. Int J Neuropsychopharmacol. 2011; 14 (6):721-734.
42. Karolewicz B, Maciag D, O'Dwyer G, Stockmeier CA, Feyissa AM, Rajkowska G. Reduced level of glutamic acid decarboxylase-67 kDa in the prefrontal cortex in major depression. Int J Neuropsychopharmacol. 2010; 13 (4):411-420.
43. Northoff G, Sibille E. Why are cortical GABA neurons relevant to internal focus in depression? A cross-level model linking cellular, biochemical and neural network findings. Mol Psychiatry. 2014; 19 (9):966-977.
44. Picciotto MR, Higley MJ, Mineur YS. Acetylcho line as a neuromodulator: cholinergic signaling shapes nervous system function and behavior. Neuron. 2012; 76 (1):116-129.
45. Lawrence JJ Cholinergic control of GABA release: emerging parallels between neocortex and hippocampus. Trends Neurosci. 2008; 31 (7):317-327.
46. Monteggia LM, Kavalali ET. Scopolamine and ketamine: evidence of convergence?. Biol Psychiatry. 2013; 74 (10):712-713.
47. Taylor SR, Badurek S, Dileone RJ, Nashmi R, Minichiello L, Picciotto MR. GABAergic and glutamatergic efferents of the mouse ventral tegmental area. J Comp Neurol. 2014; 522 (14):3308-3334.
48. Casanova E, et al. A CamKIIα iCre BAC allows brain-specific gene inactivation. Genesis. 2001; 31 (1):37-42.
49. Reynolds A, Leake D, Boese Q, Scaringe S, Marshall WS, Khvorova A. Rational siRNA design for RNA interference. Nat Biotechnol. 2004; 22 (3):326-330.
50. Ventura A, et al. Cre-lox-regulated conditional RNA interference from transgenes. Proc Natl Acad Sci U S A. 2004; 101 (28):10380-10385.
51. Paxinos G, Franklin KBJ The Mouse Brain In Stereotaxic Coordinates. 2nd ed. San Diego, California, USA: Academic Press; 2001.
52. Elsayed M, Banasr M, Duric V, Fournier NM, Licznerski P, Duman RS. Antidepressant effects of fibroblast growth factor-2 in behavioral and cellular models of depression. Biol Psychiatry. 2012; 72 (4):258-265.
53. Dutheil S, Ota KT, Wohleb ES, Rasmussen K, Duman RS. High-fat diet induced anxiety and anhedonia: impact on brain homeostasis and inflammation [published online ahead of print December 14, 2015]. Neuropsychopharmacology. doi:10.1038/npp.2015.357.
54. Wohleb ES, Patterson JM, Sharma V, Quan N, Godbout JP, Sheridan JF. Knockdown of interleukin-1 receptor type-1 on endothelial cells attenuated stress-induced neuroinflammation and prevented anxiety-like behavior. J Neurosci. 2014; 34 (7):2583-2591.